Outcomes of Adults With Relapsed/Refractory Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents at a Comprehensive Cancer Center

Relapsed/refractory acute myeloid leukemia (AML) is a devastating disease with a poor prognosis and represents a major unmet medical need. We report on a real-world academic center experience of treating 25 patients with relapsed/refractory AML using venetoclax in combination with decitabine or azac...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Front Oncol
Autors principals: Tenold, Matthew E., Moskoff, Benjamin N., Benjamin, David J., Hoeg, Rasmus T., Rosenberg, Aaron S., Abedi, Mehrdad, Tuscano, Joseph M., Jonas, Brian A.
Format: Artigo
Idioma:Inglês
Publicat: Frontiers Media S.A. 2021
Matèries:
Oncology
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7991747/
https://ncbi.nlm.nih.gov/pubmed/33777810
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2021.649209
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars